✦ LIBER ✦

Factors Associated with Toxicity and Response to Yttrium 90–Labeled Ibritumomab Tiuxetan in Patients with Indolent Non-Hodgkin's Lymphoma

✍ Scribed by Borghaei, Hossein; Wallace, Stephen G.; Schilder, Russell J.

Book ID: 119935816
Publisher: CIG Media Group, LP.
Year: 2004
Tongue: English
Weight: 113 KB
Volume: 5
Category: Article
ISSN: 1526-9655
DOI: 10.3816/clm.2004.s.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ongoing Trials with Yttrium 90–Labeled I

Ongoing Trials with Yttrium 90–Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma

✍ Micallef, Ivana N.M. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 366 KB

Safety and Efficacy of Yttrium-90 Ibritu

Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma

✍ Emmanouilides, Christos; Witzig, Thomas E.; Wiseman, Gregory A.; Gordon, Leo I.; 📂 Article 📅 2007 🏛 Mary Ann Liebert 🌐 English ⚖ 149 KB

Efficacy and safety of yttrium-90 ibritu

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma

✍ Makoto Nakagawa, Naokuni Uike, Ilseung Choi… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 211 KB

Radioisotopic Localization of90Yttrium–I

Radioisotopic Localization of90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma

✍ S. A. Jacobs; A. M. Harrison; S. H. Swerdlow; K. A. Foon; N. Avril; N. Vidnovic; 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 589 KB

Combining Yttrium 90–Labeled Ibritumomab

Combining Yttrium 90–Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's Lymphoma

✍ Winter, Jane N. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 246 KB

Long-term responses in patients with rec

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

✍ Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB

## Abstract ## BACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. ## METHODS. Data on patients with recurring NHL treated w